提供支持According to VCBeat, on September 5th, 2019, Polaris Biology, a clinical solution provider for accurate single-cell diagnosis, announced that it had completed A+ round of financing.
The funds will be used to promote the technical development and transformation application of the single-cell high-throughput multi-group diagnosis platform with mass spectrometry technology. This round was led by Baidu Ventures. The details of this financing were not disclosed.
Prior to this financing, Polaris Biology had completed the Series A financing of $8.25 million invested by ETP, Morningside Venture Capital and Volcanics Venture in January 2019.
Multiparameter high-flux detection at the single-cell level is based on mass spectrometry technology. By labeling antibodies with isotopic metal probes, the technology has broken through the limitation of fluorescence detection channels with rapid analysis and accurate detection.
"At present, Polaris Biology’s mass spectrometry technology can simultaneously complete single-cell expression level analysis of many proteins including PD-1, PD-L1, and LAG3, and detect specific markers such as lymphocytes, monocytes, and MDSC. Based on mass spectrometry, we are able to support clinical and scientific research to the interactions among tumor cells, immune system and therapeutic system with high resolution, avoid the occurrence of side effects, and provide a system perspective for the development of new therapies.", said Sun Shuangwu, the partner of Polaris Biology’s tumor immunity department.
BV invests in deep tech companies pushing the frontiers that enable artificial intelligence as well as companies building applications that were previously impossible without AI.
BV is a financial investor focusing on the Seed, Series A, and Series B of companies across China, North America & Europe, with teams in all three geographies.
渝公网安备 50011202502165号
